Heuft H G, Berg T, Schreier E, Künkel U, Tacke M, Schwella N, Hopf U, Salama A, Huhn D
Virchow-Clinic, Department of Internal Medicine, Hematology/Oncology, Humboldt University, Germany.
Vox Sang. 1998;74(3):161-7.
The infectiousness and clinical relevance of the newly discovered blood-borne Flaviviridae-like agent, termed hepatitis G virus (HGV), are not well understood.
Twenty-three transfusion recipients of two HGV-affected long-term blood donors were studied for HGV genome and antibodies to the putative envelope 2 glycoprotein (anti-E2) of HGV. Nine recipients had nonhematological disorders and 14 suffered from severe hematological diseases and 7 of them received allogeneic bone marrow or blood stem cell transplantation. The molecular epidemiology of the observed HGV infection was studied by direct sequencing of parts of the 5'-noncoding region, NS3, and NS5 region of HGV in the 2 long-term donors and in their 6 recipients who became HGV RNA positive. Additionally, 549 individuals-homologous (n = 254) and autologous blood donors (n = 202), and medical staff (n = 89)--were investigated for the presence of HGV RNA.
HGV RNA in serum was found in 15 of the 23 (65%) transfusion recipients with known exposure of HGV-contaminated blood. Seven of the remaining 8 recipients showed only an anti-E2 response, indicating previous HGV infection with spontaneous clearance of the virus. In one recipient neither HGV RNA nor anti-E2 could be detected. Molecular evidence for HGV transmission by the 2 donors was found in 3 of the 6 recipients studied. The alanine aminotransferase levels were not significantly different in the HGV RNA positive and negative recipients, and none of the 23 recipients developed posttransfusion hepatitis. Persistent HGV infection was observed especially in recipients with severe hematological disorders or in those in whom intensive immunosuppressive treatment was necessary. Of the 549 individuals studied, 10 (1.8%) were healthy carriers of HGV RNA.
The persistence of transfusion-acquired HGV infection is not associated with acute or chronic hepatitis, but may be influenced by the recipient's underlying disease.
新发现的一种血源性病原体,称为庚型肝炎病毒(HGV),其传染性及临床相关性尚未完全明确。
对两名受HGV感染的长期献血者的23名输血受者进行了HGV基因组及针对假定包膜2糖蛋白(抗-E2)的抗体检测。9名受者患有非血液系统疾病,14名患有严重血液系统疾病,其中7名接受了同种异体骨髓或造血干细胞移植。通过对两名长期献血者及其6名HGV RNA呈阳性的受者的HGV 5'-非编码区、NS3和NS5区部分片段进行直接测序,研究了观察到的HGV感染的分子流行病学。此外,还对549名个体——同源献血者(n = 254)、自体献血者(n = 202)和医护人员(n = 89)——进行了HGV RNA检测。
在已知接触过受HGV污染血液的23名输血受者中,15名(65%)血清中检测到HGV RNA。其余8名受者中有7名仅表现出抗-E2反应,表明既往感染过HGV且病毒已自发清除。1名受者未检测到HGV RNA及抗-E2。在研究的6名受者中,有3名发现了两名献血者传播HGV的分子证据。HGV RNA阳性和阴性受者的丙氨酸转氨酶水平无显著差异,23名受者均未发生输血后肝炎。尤其在患有严重血液系统疾病或需要强化免疫抑制治疗的受者中观察到持续性HGV感染。在研究的549名个体中(1.8%)为HGV RNA健康携带者。
输血获得性HGV感染的持续性与急性或慢性肝炎无关,但可能受受者基础疾病的影响。